Blog
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
Halozyme Therapeutics HALO reported second-quarter 2025 adjusted earnings of $1.54 per share, which comprehensively beat the Zacks Consensus Estimate of $1.23. Earnings rose 69.2% year over year.
Super Micro Computer Q4 Earnings Miss Estimates, Revenues Rise Y/Y
Super Micro Computer SMCI reported fourth-quarter fiscal 2025 non-GAAP earnings of 41 cents per share, which missed the Zacks Consensus Estimate by 6.8%. The bottom line declined 34.9% on a
PGR vs. BRK.B: Which Insurer is a Safer Investment Option?
The U.S. auto insurance market is projected to reach $349.37 billion by 2025, with an average spending per capita of $1020, according to Statista. Despite a slowdown in rate increases, the average
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark
Beam Therapeutics BEAM incurred a loss of $1.00 per share in the second quarter of 2025, which was narrower than the Zacks Consensus Estimate of a loss of $1.04. The company had reported a loss of
Implied Volatility Surging for Chord Energy Stock Options
Investors in Chord Energy Corporation CHRD need to pay close attention to the stock based on moves in the options market lately. That is because the Sept. 19, 2025 $65.00 Call had some of the
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
Recursion Pharmaceuticals RXRX reported a loss of 41 cents per share in the second quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 35 cents. The company had incurred a loss of
Will Coca-Cola's Coffee Bet Perk Up Its Global Beverage Sales?
The Coca-Cola Company’s KO long-standing ambition to break into the global coffee segment remains a work in progress. The company’s acquisition of Costa aimed to unlock multiple verticals, including
Palomar Q2 Earnings, Revenues Top Estimates, Premiums Rise Y/Y
Palomar Holdings Inc. PLMR reported second-quarter 2025 operating income of $1.76 per share, which beat the Zacks Consensus Estimate by 4.7%. The bottom line increased 40.8% year over year. The
Why Home BancShares (HOMB) is a Top Dividend Stock for Your Portfolio
Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But for income investors, generating consistent cash flow from
Why Associated Banc-Corp (ASB) is a Top Dividend Stock for Your Portfolio
Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But for income investors, generating consistent cash flow from
PCB Bancorp (PCB) Could Be a Great Choice
Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. However, when you're an income investor, your
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is
Are You Looking for a High-Growth Dividend Stock?
All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is
Why CNB Financial (CCNE) is a Great Dividend Stock Right Now
All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is
Why COPT Defense (CDP) is a Great Dividend Stock Right Now
All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
Ultragenyx Pharmaceutical RARE reported second-quarter 2025 loss of $1.17 per share, narrower than the Zacks Consensus Estimate of a loss of $1.27. The company had incurred a loss of $1.52 per share
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises
Esperion Therapeutics ESPR incurred a loss of 2 cents per share in the second quarter of 2025, which was much narrower than the Zacks Consensus Estimate of a loss of 17 cents. The company had
BMBL or FFIV: Which Is the Better Value Stock Right Now?
Investors interested in Internet - Software stocks are likely familiar with Bumble Inc. (BMBL) and F5 Networks (FFIV). But which of these two stocks presents investors with the better value
VEOEY vs. AWK: Which Stock Is the Better Value Option?
Investors looking for stocks in the Utility - Water Supply sector might want to consider either Veolia Environnement SA (VEOEY) or American Water Works (AWK). But which of these two stocks offers
PYPL or MA: Which Is the Better Value Stock Right Now?
Investors interested in Financial Transaction Services stocks are likely familiar with Paypal (PYPL) and MasterCard (MA). But which of these two stocks is more attractive to value investors? We'll
GEF or PKG: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Containers - Paper and Packaging sector might want to consider either Greif (GEF) or Packaging Corp. (PKG). But which of these two stocks is more attractive to
BBD or HDB: Which Is the Better Value Stock Right Now?
Investors interested in Banks - Foreign stocks are likely familiar with Banco Bradesco (BBD) and HDFC Bank (HDB). But which of these two stocks presents investors with the better value opportunity
TFX vs. SONVY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Teleflex (TFX) and SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to




